Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Interventional, Open-label, Three-group Study to Determine the Pharmacokinetic Properties of Single Oral Dosing of Lu AE58054 in Patients With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of Lu AE58054 following a single oral dose of Lu AE58054

Inclusion Criteria:

• Men and women aged between 40 and 65 years (inclusive) with a body mass index between 19 and 32 kg/m2 (inclusive).
• Group 1: Patients with mild hepatic impairment (Child-Pugh's Criteria A, score 5-6)
• Group 2: Patients with moderate hepatic impairment (Child-Pugh's Criteria B, score 7-9)
• Group 3: Healthy subjects with normal hepatic function

Other pre-defined inclusion and exclusion criteria may apply.